Viewing Study NCT04736394

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 1:39 AM

Ignite Modification Date: 2025-12-27 @ 11:09 PM

Study NCT ID: NCT04736394

Status: RECRUITING

Last Update Posted: 2022-02-22

First Post: 2021-01-29

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

Sponsor: Jiangsu Yahong Meditech Co., Ltd aka Asieris

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module